Search Within

Daniel C Danila

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (12)
  2. Meeting Abstract (12)
Groups
  1. Department of Medicine (24)
  2. Genitourinary Oncology Service (24)
  3. Molecular Pharmacology and Chemistry Program Faculty (24)
  4. Sloan Kettering Institute Faculty (24)
  5. Solid Tumor Oncology Division (24)
  6. GSK Faculty (22)

More Groups

People
  1. Howard Scher (22)
  2. Steven Larson (20)
  3. Michael Morris (19)
  4. Martin Fleisher (11)
  5. Dana Rathkopf (10)
  6. Susan Slovin (10)

More People

Years
  1. 2022 (1)
  2. 2020 (1)
  3. 2019 (2)
  4. 2017 (1)
  5. 2016 (1)
  6. 2015 (1)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Journal of Nuclear Medicine (3)
  3. Cancer Research (1)
  4. Cell (1)
  5. Clinical Cancer Research (1)
  6. Clinical Chemistry (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. American Association for Cancer Research (3)
  3. Society of Nuclear Medicine (3)
  4. Elsevier Inc. (2)
  5. Elsevier Science, Inc. (2)
  6. American Association for Clinical Chemistry (1)

More Publishers

Results (24)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Morris, M. J.; Fox, J. J.; Danila, D. C.; Slovin, S. F.; Hager, J. H.; Rix, P. J.; Chow-Maneval, E.; Chen, I.; Gonen, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Monitoring the clinical outcomes in advanced prostate cancer: What imaging modalities and other markers are reliable?
    Journal Article

    Morris, M. J.; Autio, K. A.; Basch, E. M.; Danila, D. C.; Larson, S.; Scher, H. I.
    Seminars in Oncology (2013)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Chudow, J. J.; Morris, M. J.; Slovin, S. F.; Fine, S.; Fox, J. J.; Larson, S. M.; Rosen, N.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
    Journal Article

    Danila, D. C.; Morris, M. J.; de Bono, J. S.; Ryan, C. J.; Denmeade, S. R.; Smith, M. R.; Taplin, M. E.; Bubley, G. J.; Kheoh, T.; Haqq, C.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    Journal Article

    Scher, H. I.; Anand, A.; Rathkopf, D.; Shelkey, J.; Morris, M. J.; Danila, D. C.; Larson, S.; Humm, J.; Fleisher, M.; Sawyers, C. L.; more...
    Lancet (2010)

    Fulltext@MSK | Save